Table 1 Patient characteristics and laboratory findings from AAA patient groups with and without optimal PCR*.
| Variables | Total (n=205) | PCR(+) (n=79) | PCR(−) (n=126) | P-value |
|---|---|---|---|---|
| Age (years) | 75.0±0.5 (73.9–76.0) | 73.8±0.9 (72.0–75.6) | 76.1±0.7 (74.7–77.6) | 0.05 |
| Sex (male) | 173 (84) | 74 (94) | 99 (79) | 0.005 |
| Body mass index | 23.1±0.2 (22.6–23.5) | 23.3±0.4 (22.4–24.2) | 22.8±0.3 (22.1–23.5) | 0.37 |
| Smoking history | ||||
| Current | 48 (24) | 21 (27) | 27 (22) | 0.04 |
| Past | 56 (27) | 14 (18) | 42 (34) | |
| Never | 100 (49) | 44 (56) | 56 (45) | |
| Hypertension | 169 (82) | 62 (78) | 107 (85) | 0.26 |
| Diabetes mellitus | 51 (25) | 18 (23) | 33 (26) | 0.62 |
| Dyslipidaemia | 74 (36) | 31 (39) | 43 (34) | 0.46 |
| Coronary artery disease | 65 (32) | 21 (27) | 44 (35) | 0.22 |
| Cerebrovascular disease | 54 (26) | 24 (30) | 30 (24) | 0.33 |
| Ejection fraction (%) | 65.4±0.8 (63.8–67.1) | 65.0±1.4 (62.2–67.7) | 65.9±1.1 (63.7–68.0) | 0.60 |
| FEV1.0% | 68.6±0.8 (67.0–70.2) | 67.5±1.4 (64.7–70.2) | 69.8±1.1 (67.6–71.9) | 0.19 |
| Atrial fibrillation | 18 (9) | 5 (6) | 13 (10) | 0.45 |
| End-stage renal disease | 6 (3) | 2 (3) | 4 (3) | 1.00 |
| Medication | ||||
| Statin | 105 (51) | 45 (57) | 60 (48) | 0.20 |
| Antiplatelet therapy | ||||
| None | 99 (48) | 36 (46) | 63 (50) | 0.57 |
| SAPT | 84 (41) | 36 (46) | 48 (38) | |
| DAPT | 22 (11) | 7 (9) | 15 (12) | |
| Anticoagulant therapy | 18 (9) | 8 (10) | 10 (8) | 0.62 |
| Laboratory data | ||||
| White blood cells (103/µL) | 6.6±0.1 (6.3–6.8) | 6.6±0.2 (6.1–7.0) | 6.5±0.2 (6.1–6.9) | 0.79 |
| Haemoglobin (g/dL) | 12.8±0.1 (12.5–13.0) | 12.8±0.2 (12.4–13.2) | 12.7±0.2 (12.4–13.0) | 0.55 |
| Platelet count (103/µL) | 188±4 (180–195) | 173±6 (160–186) | 194±5 (183–204) | 0.01 |
| C-reactive protein (mg/dL) | 0.75±0.01 (0.51–0.99) | 0.73±0.2 (0.33–1.13) | 0.70±0.16 (0.38–1.00) | 0.88 |
| Albumin (g/dL) | 4.02±0.03 (3.96–4.09) | 4.02±0.05 (3.91–4.13) | 4.02±0.04 (3.94–4.11) | 0.98 |
| Creatinine (mg/dL) | 1.14±0.06 (1.03–1.26) | 1.20±0.1 (1.00–1.41) | 1.15±0.08 (0.99–1.31) | 0.63 |
| PT-INR | 1.07±0.01 (1.05–1.09) | 1.09±0.02 (1.04–1.13) | 1.07±0.02 (1.04–1.10) | 0.54 |
| APTT-T (s) | 33.1±0.4 (32.4–33.8) | 33.4±0.6 (32.2–34.6) | 33.3±0.5 (32.3–34.2) | 0.88 |
*Optimal PCR was defined as ≥118% by ROC analysis. Continuous data are shown as mean±standard error and categorical data as numbers (%). FEV1.0%: forced expiratory volume % in 1 s; SAPT: single antiplatelet therapy; DAPT: dual antiplatelet therapy; PT-INR: prothrombin time-international normalized ratio; APTT-T: activated partial thromboplastin time; AAA: abdominal aortic aneurysm; PCR: platelet count recovery